VANCOUVER, BC / ACCESS Newswire / April 7, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...
DoW-funded Phase 2a trial led by University of North Carolina at Chapel Hill (UNC) Institute for Trauma Recovery Positive outcomes from trial can potentially impact Veteran Affairs/Department of War ...
VANCOUVER, BC / ACCESS Newswire / April 7, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery syst ...
Called “gas station heroin,” kratom products have grown in use locally and beyond for pain relief and easing anxiety and ...
Psychedelic toad secretions and celebrity reports of psychological recovery from use intrigued researchers, who developed a ...
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive ...
The Healthy @Reader's Digest on MSN
Ketamine therapy: A medical doctor explains its use for treatment-resistant depression
A Cleveland Clinic psychiatrist explains how ketamine therapy is transforming depression treatment—and why it works when ...
When methylone was finally banned in 2011, unregulated chemists simply tweaked the molecule to evade the ban, creating new ...
A woman who admitted to selling Matthew Perry the ketamine that killed him is set to be sentenced. Jasveen Sangha will be the ...
The FDA granted Priority Review to the supplemental BLA (sBLA) for efgartigimod alfa-fcab for the treatment of adults with acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia ...
New psychoactive substances (NPS) are a class of artificially designed and synthesized chemical substances designed to mimic the pharmacological effects of traditional drugs. They are characterized by ...
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results